| Description | AVX-001, a cytosolic phospholipase A2 (cPLA2) inhibitor, is used potentially for the treatment of psoriasis. |
| Synonyms | FP-025, AKH-217, AKH217, AVX001, FP025 |
| molecular weight | 386.51 |
| Molecular formula | C21H29F3OS |
| CAS | 300553-18-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Omland SH, Habicht A, Damsbo P, Wilms J, Johansen B, Gniadecki R. A randomized, double-blind, placebo-controlled, dose-escalation first-in-man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasis. J Eur Acad Dermatol Venereol. 2017 Jan 20. doi: 10.1111/jdv.14128. [Epub ahead of print] PubMed PMID: 28107559. 2. Huwiler A, Feuerherm AJ, Sakem B, Pastukhov O, Filipenko I, Nguyen T, Johansen B. The ω3-polyunsaturated fatty acid derivatives AVX001 and AVX002 directly inhibit cytosolic phospholipase A(2) and suppress PGE(2) formation in mesangial cells. Br J Pharmacol. 2012 Dec;167(8):1691-701. doi: 10.1111/j.1476-5381.2012.02114.x. PubMed PMID: 22831644; PubMed Central PMCID: PMC3525871. |